Ascentage Pharma Group International
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 35.42 | -100% | -8.11 | -100% |
| P/S |
|
30.33 | 7.59 | 299.77% |
|
|
| P/BV |
|
95.34 | 3.68 | 2487.16% |
|
|
| P/FCF |
|
-10.23 | 55.3 | -118.5% |
|
|
| Ev/Ebitda |
|
-8.05 | 2.91 | -376.96% |
|
|
| Ev/S |
|
33.5 | 23.72 | 41.27% |
|
|
| Ev/FCF |
|
-9.5 | 63.78 | -114.89% |
|
|
| E/P |
|
-0.1156 | 0.0326 | -454.27% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
-367.87 | -11.9 | 2990.95% | -3396.39 | -89.17% |
| ROE |
|
-394.66 | 5.19 | -7709.47% |
|
|
| ROA |
|
-34.73 | 3.47 | -1100.95% |
|
|
| ROIC |
|
0 | 0 | 0% |
|
|
| ROS |
|
-416.98 | -11.49 | 3530.06% |
|
|
| ROCE |
|
0 | 6.04 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-2.16 | 0.7755 | -379.04% | -1.47 | +46.86% |
| Nеt Debt/Ebitda |
|
-0.8506 | 0.0127 | -6780.89% |
|
|
| Debt/Ratio |
|
0.7159 | 0.1229 | 482.71% |
|
|
| Debt/Equity |
|
1.01 | 0.802 | 25.39% |
|
|
| Debt/Net Income |
|
-1.93 | 1.76 | -210.03% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 2.43 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 1.21 | -100% | ||
| DSI |
|
0 | 0.563 | -100% |
|
|
| Average dividend growth |
|
0 | 3.2 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 1.82 | -100% |
|
|
| Average percentage for payments |
|
0 | 23.96 | -100% |
|
|
| Difference from average difference in sector |
|
-2.43 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
1429.55 | 28.69 | 4882.75% | ||
| Growth impulse Ebitda in 5 years |
|
114.36 | -40.52 | -382.23% | ||
| Growth impulse Net Income in 5 years |
|
-37.49 | 94.84 | -139.53% | ||
| Growth impulse FCF in 5 years |
|
44.52 | 91.41 | -51.3% | ||
| Growth impulse EPS in 5 years |
|
321.97 | -118.14 | -372.53% |
IP Score
3.92/10
